Pharmacogenetics and Genomics

Papers
(The H4-Index of Pharmacogenetics and Genomics is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes19
Association of Genetic Variation in CES, UGT, ABC, and SLCO with Irinotecan Infusion Reactions and Severe Toxicity: Erratum16
Application of risk priority number of failure mode and effects analysis to drug–variant pairs for severe cutaneous adverse reactions in Korean and American populations14
MEG3 in hematologic malignancies: from the role of disease biomarker to therapeutic target13
Establishing national reference materials for genetic testing of cytochrome P45013
Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients11
Pharmacogenetic testing coverage by Canadian insurance providers11
Luteal phase stimulation in double ovarian stimulation cycles is not affected by the follicle-stimulating hormone (FSH) receptor genotype: double ovarian stimulation is beneficial independently of the11
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation10
Common dihydropyrimidinase (DPYS) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort10
The prevalence of pharmacogenetic testing in the United States10
0.067579030990601